Gorfinkel, Lev
Raghunandan, Sharmila http://orcid.org/0000-0002-1149-8524
Watkins, Benjamin
Hebert, Kyle
Neuberg, Donna S. http://orcid.org/0000-0003-2566-3145
Bratrude, Brandi http://orcid.org/0000-0002-1498-1001
Betz, Kayla
Yu, Alison
Choi, Sung W. http://orcid.org/0000-0002-6321-3834
Davis, Jeffrey
Duncan, Christine
Giller, Roger
Grimley, Michael http://orcid.org/0000-0003-2056-5167
Harris, Andrew C.
Jacobsohn, David http://orcid.org/0000-0001-6119-3270
Lalefar, Nahal
Farhadfar, Nosha
Pulsipher, Michael A.
Shenoy, Shalini
Petrovic, Aleksandra
Schultz, Kirk R.
Yanik, Gregory A.
Blazar, Bruce R.
Horan, John T.
Langston, Amelia http://orcid.org/0000-0003-0649-1915
Kean, Leslie S. http://orcid.org/0000-0003-0475-3926
Qayed, Muna
Article History
Received: 7 August 2023
Revised: 20 December 2023
Accepted: 7 February 2024
First Online: 21 February 2024
Competing interests
: MQ. Consulting or Advisory Role: Novartis, Mesoblast. Travel, Accommodations, Expenses: Novartis. LSK. Consulting or Advisory Role: HiFiBio, Mammoth Biosciences. Research Funding: Regeneron, Gilead Sciences, Novartis, Tessera Therapeutics, Tonix Pharmaceuticals, Bristol Myers Squibb. Patents, Royalties, Other Intellectual Property: Licensing Fees for ABA2 clinical trial data. No other potential conflicts of interest were reported.